About

THE ONLY FDA-APPROVED TREATMENT FOR MOLLUSCUM

FOR AGES
2+

YCANTH™ defines the treatment experience

Photo is illustrative and not representative of all patients.

A consistent formulation administered by a trained healthcare professional2

The innovative applicator is designed for precise delivery of YCANTH to each molluscum lesion4

Applicator Diagram
  1. Small applicator opening allows for targeting of each lesion
  2. A coloring agent helps prevent multiple applications to the same lesion
  3. GMP-controlled, consistent formulation of 0.7% (w/v) cantharidin
  4. Single-use applicator
  5. Prepared by breaking the glass ampule with a YCANTH Break Tool to release YCANTH into the applicator
  6. Contains a bittering agent to help deter ingestion
Applicator Diagram
  1. Small applicator opening allows for targeting of each lesion
  2. A coloring agent helps prevent multiple applications to the same lesion
  3. GMP-controlled, consistent formulation of 0.7% (w/v) cantharidin
  4. Single-use applicator
  5. Prepared by breaking the glass ampule with a YCANTH Break Tool to release YCANTH into the applicator
  6. Contains a bittering agent to help deter ingestion

See the step-by-step administration instructions.

WATCH VIDEO

Applicator is not to scale.

GMP=good manufacturing practice.

YCANTH is easily applied in the office

Using the small-tip applicator, apply only enough to cover each lesion4*

  • YCANTH may be administered every 3 weeks, as needed4
  • If YCANTH comes in contact with healthy skin during application, it should be removed with a cotton swab or gauze4
  • Avoid application near the eyes and mucosal tissues, and to adjacent healthy skin4

YCANTH should be removed with soap and water 24 hours after treatment4

  • Do not cover treated lesions with bandages4
  • If severe blistering, severe pain, or other adverse reactions occur, remove YCANTH prior to the recommended 24 hours after administration4

What you should know before administering YCANTH4

  • Verrica is committed to providing a training program to ensure an optimal experience
  • Counsel your patients to avoid contact with the treatment areas, including oral contact
  • YCANTH is flammable; avoid fire, flame, or smoking near lesion(s) during treatment
  • YCANTH is not for oral, mucosal, or ophthalmic use

*

YCANTH should be applied only to lesions that are practically and medically safe to treat.4

Applicator

Applicator is not to scale.

Consistent formulation, precise control.2

In two phase 3 clinical trials, significantly more patients treated with YCANTH achieved complete clearance of new and baseline lesions than with vehicle within 12 weeks (P<0.0001)1,2

CAMP-1:  46% vs 18% (P<0.0001)3 CAMP-2:  54% vs 13% (P<0.0001)3
DISCOVER THE DATA

YCANTH is a vesicant. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH. No serious adverse reactions were reported in clinical trials.4

For additional YCANTH resources:

CLICK HERE

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.

INDICATION

YCANTH (cantharidin) topical solution, 0.7% is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: None.

WARNINGS AND PRECAUTIONS:

  • YCANTH is for topical use only. YCANTH is not for oral, mucosal, or ophthalmic use. Life threatening or fatal toxicities can occur if YCANTH is administered orally. Avoid contact with the treatment area, including oral contact, after treatment. Ocular toxicity can occur if YCANTH comes in contact with eyes. If YCANTH gets in eyes, flush eyes with water for at least 15 minutes.
  • Local Skin Reactions: Reactions at the application site may occur, including vesiculation, pruritus, pain, discoloration, and erythema. Avoid application near eyes and mucosal tissue, and to healthy skin. If YCANTH contacts any unintended surface, or healthy skin, immediately remove. If severe local skin reactions occur, remove prior to the recommended 24 hours after treatment.
  • YCANTH is flammable, even after drying. Avoid fire, flame or smoking near lesion(s) during treatment and after application until removed.

ADVERSE REACTIONS:

The most common (incidence ≥1%) reactions are the following local skin reactions at the application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, application site dryness, edema, and erosion. Local skin reactions at the application site were observed in 97% of subjects treated with YCANTH during clinical trials. These local skin reactions are expected and related to the anticipated blistering response of the skin to cantharidin.

DRUG INTERACTIONS:

No studies evaluating the drug interaction potential of cantharidin have been conducted.

USE IN SPECIFIC POPULATIONS:

Pregnancy: There are no available data with use of YCANTH in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Given that systemic exposure to cantharidin following topical administration is low, maternal use is not expected to result in fetal exposure to the drug.

Lactation: Avoid application of YCANTH topical solution to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

OVERDOSAGE:

Oral ingestion of cantharidin has resulted in renal failure, blistering and severe damage to the gastrointestinal tract, coagulopathy, seizures, and flaccid paralysis.

Please see full Prescribing Information.

To report SUSPECTED ADVERSE REACTIONS, contact Verrica Pharmaceuticals Inc. at 1-877-VERRICA (1-877-837-7422), or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Local skin reactions are expected and should be reported if they are severe.